Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WX-UK1
- Development stage
- Phase 1
- Lead developer
- Heidelberg Pharma
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
WX-UK1 is a 3-amidinophenylalanine-based non-cytotoxic small molecule inhibitor developed primarily by Wilex (now Heidelberg Pharma AG) as an antineoplastic agent. It acts by inhibiting serine proteases—specifically the urokinase-type plasminogen activator (uPA) system and related trypsin-like enzymes—which are implicated in tumor cell invasion, metastasis formation, and primary tumor growth. Preclinical studies demonstrated that WX-UK1 can reduce both metastasis and primary tumor size in animal models of breast cancer and other solid tumors. The drug was investigated for use in various solid tumors including gastric, ovarian, pancreatic cancers and participated in phase I clinical trials (often combined with capecitabine or gemcitabine). Clinical development was discontinued after early-phase trials[1][2][3][4][5].
- Other names
- WX-UK1WX-UK-1WX-UK 1WX UK1WXUK1WXUK-1WXUK 1
02
Targets
PRSS1 (Trypsin family)PLAU (uPA)PLAUR (Urokinase plasminogen activator receptor)
Beyond the preview
Go deeper on WX-UK1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WX-UK1.